Selexipag for treating pulmonary arterial hypertension

Published on 13 Sep 2024
Last Updated on 16 Sep 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

• Selexipag 200 mcg, 400 mcg, 600 mcg and 800 mcg tablet, to be added as the second or third drug in a combination treatment for pulmonary arterial hypertension, in line with the following criteria:

  • Patient is already receiving an endothelin receptor antagonist and/or a phosphodiesterase type 5 inhibitor at maximum tolerated doses; and

  • Prior to adding selexipag treatment, patient is assessed to have intermediate to high risk of 1-year mortality (according to the European Society of Cardiology/European Respiratory Society risk-stratification tool) during follow-up.

Funding status

Selexipag 200 mcg, 400 mcg, 600 mcg and 800 mcg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 November 2025.

Higher-strength tablets of selexipag (1,000 mcg, 1,200 mcg, 1,400 mcg and 1,600 mcg) have not been recommended for inclusion on the MAF as they are currently not marketed in Singapore.

Selexipag for treating pulmonary arterial hypertension (Updated 16 Sep 2025) [PDF, 132 KB]

PES Selexipag for treating pulmonary arterial hypertension (Updated 16 Sep 2024) [PDF, 96 KB]